Pathological gambling associated with aripiprazole or dopamine replacement therapy do patients share the same features? a review

Journal of Clinical Psychopharmacology

Volumn 36, Issue 1, 2016, Pages 63-70

  Grall Bronnec, Marie ^a,b   Sauvaget, Anne ^a   Perrouin, Fanny ^c   Leboucher, Juliette ^a   Etcheverrigaray, François ^c   Challet Bouju, Gaëlle ^a,b   Gaboriau, Louise ^c   Derkinderen, Pascal ^a   Jolliet, Pascale ^b,c   Victorri Vigneau, Caroline ^b,c  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b Universite de Nantes   (France)

^c Department of Pharmacology ^*  (France)

Author keywords

Agonist; Aripiprazole; Dopamine receptor; Dopamine replacement therapy; Gambling disorder; Impulse control disorder

Indexed keywords

ARIPIPRAZOLE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT;

COMORBIDITY; EMOTION; HUMAN; MENTAL DISEASE; MOOD DISORDER; PATHOLOGICAL GAMBLING; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SENSATION SEEKING; SUBSTITUTION THERAPY; SYSTEMATIC REVIEW; WITHDRAWAL SYNDROME; ADOLESCENT; AGONISTS; CHEMICALLY INDUCED; GAMBLING; IMPULSE CONTROL DISORDER; RISK FACTOR;

ADOLESCENT; ARIPIPRAZOLE; DISRUPTIVE, IMPULSE CONTROL, AND CONDUCT DISORDERS; DOPAMINE AGONISTS; GAMBLING; HUMANS; RECEPTORS, DOPAMINE D2; RISK FACTORS;

EID: 84952987402     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000444     Document Type: Review

References (77)

1. Ambermoon P, Carter A, Hall WD, et al. Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field. Addiction. 2011;106:283-293.
2. Gallagher DA, O'Sullivan SS, Evans AH, et al. Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord. 2007;22:1757-1763.
3. Voon V, Fernagut PO, Wickens J, et al. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol. 2009;8:1140-1149.
4. Seedat S, Kesler S, Niehaus DJ, et al. Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depress Anxiety. 2000;11:185-186.
5. Molina JA, Sainz-Artiga MJ, Fraile A, et al. Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment? Mov Disord. 2000;15:869-872.
6. Driver-Dunckley E, Samanta J, StacyM. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology. 2003;61:422-423.
7. Avanzi M, Uber E, Bonfa F. Pathological gambling in two patients on dopamine replacement therapy for Parkinson's disease. Neurol Sci. 2004;25:98-101.
8. Dodd ML, Klos KJ, Bower JH, et al. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol. 2005;62:1377-1381.
9. Lu C, Bharmal A, Suchowersky O. Gambling and Parkinson disease. Arch Neurol. 2006;63:298.
10. Szarfman A, Doraiswamy PM, Tonning JM, et al. Association between pathologic gambling and parkinsonian therapy as detected in the Food and Drug Administration Adverse Event database. Arch Neurol. 2006;63:299-300.
11. Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol. 2006;63:969-973.
12. Voon V, Hassan K, ZurowskiM, et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology. 2006;66:1750-1752.
13. Grosset KA, Macphee G, Pal G, et al. Problematic gambling on dopamine agonists: not such a rarity. Mov Disord. 2006;21:2206-2208.
14. Voon V, Thomsen T, Miyasaki JM, et al. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol. 2007;64:212-216.
15. Singh A, Kandimala G, Dewey RB Jr, et al. Risk factors for pathologic gambling and other compulsions among Parkinson's disease patients taking dopamine agonists. J Clin Neurosci. 2007;14:1178-1181.
16. Drapier D, Drapier S, Sauleau P, et al. Pathological gambling secondary to dopaminergic therapy in Parkinson's disease. Psychiatry Res. 2006;144: 241-244.
17. Imamura A, Uitti RJ, Wszolek ZK. Dopamine agonist therapy for Parkinson disease and pathological gambling. Parkinsonism Relat Disord. 2006;12:506-508.
18. O'Sullivan SS, Lees AJ. Pathological gambling in Parkinson's disease. Lancet Neurol. 2007;6:384-386.
19. Crockford D, Quickfall J, Currie S, et al. Prevalence of problem and pathological gambling in Parkinson's disease. J Gambl Stud. 2008;24: 411-422.
20. Lee JY, Kim JM, Kim JW, et al. Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease. Parkinsonism Relat Disord. 2010;16:202-207.
21. Santangelo G, Vitale C, Trojano L, et al. Cognitive dysfunctions and pathological gambling in patients with Parkinson's disease. Mov Disord. 2009;24:899-905.
22. Santangelo G, Barone P, Trojano L, et al. Pathological gambling in Parkinson's disease. A comprehensive review. Parkinsonism Relat Disord. 2013;19:645-653.
23. Rang HP, Dale MM, Ritter JM, et al. Rang & Dale's Pharmacology. 7th ed. London, United Kingdom: Elsevier Churchill Livingstone; 2012:792.
24. Gavaudan G, Magalon D, Cohen J, et al. Partial agonist therapy in schizophrenia: relevance to diminished criminal responsibility. J Forensic Sci. 2010;55:1659-1662.
25. Roxanas MG. Pathological gambling and compulsive eating associated with aripiprazole. Aust N Z J Psychiatry. 2010;44:291.
26. Cohen J, Magalon D, Boyer L, et al. Aripiprazole-induced pathological gambling: a report of 3 cases. Curr Drug Saf. 2011;6:51-53.
27. Smith N, Kitchenham N, Bowden-Jones H. Pathological gambling and the treatment of psychosis with aripiprazole: case reports. Br J Psychiatry. 2011;199:158-159.
28. Gaboriau L, Victorri-Vigneau C, Gerardin M, et al. Aripiprazole: a new risk factor for pathological gambling? A report of 8 case reports. Addict Behav. 2014;39:562-565.
29. Sharpe L. A reformulated cognitive-behavioral model of problem gambling. A biopsychosocial perspective. Clin Psychol Rev. 2002;22:1-25.
30. Iancu I, Lowengrub K, Dembinsky Y, et al. Pathological gambling: an update on neuropathophysiology and pharmacotherapy. CNS Drugs. 2008;22:123-138.
31. Blaszczynski A, Nower L. A pathways model of problem and pathological gambling. Addiction. 2002;97:487-499.
32. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006-1012.
33. Toce-Gerstein M, Gerstein DR, Volberg RA. A hierarchy of gambling disorders in the community. Addiction. 2003;98:1661-1672.
34. Potenza MN, Maciejewski PK, Mazure CM. A gender-based examination of past-year recreational gamblers. J Gambl Stud. 2006;22:41-64.
35. Toneatto T, Millar G. Assessing and treating problem gambling: empirical status and promising trends. Can J Psychiatry. 2004; 49:517-525.
36. Lecrubier Y, Sheehan D, Weiller E, et al. The Mini International Neuropsychiatric Interview (MINI), a short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry. 1997;12:224-231.
37. Ward MF, Wender PH, Reimherr FW. The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry. 1993;150:885-890.
38. Whiteside SP, Lynam DR, Miller JD, et al. Validation of the UPPS Impulsive Behaviour Scale: a four model of impulsivity. Eur J Pers. 2005;19:559-574.
39. Cloninger CR. The Temperament and Character Inventory-125 (TCI-125; version 1). St Louis, MO: Washington University Center for Psychobiology of Personality; 1992.
40. Breen RB, Zuckerman M. 'Chasing' in gambling behavior: personality and cognitive determinants. Pers Individividual Diffferences. 1999;27:1097-1111.
41. Boutin C. Le jeu: chance ou stratégie? Choisir librement la place du jeu dans votre vie. Montréal, Canada: Les Editions de l'Homme; 2010:272.
42. Bandini F, Primavera A, Pizzorno M, et al. Using STN DBS and medication reduction as a strategy to treat pathological gambling in Parkinson's disease. Parkinsonism Relat Disord. 2007;13:369-371.
43. Bosco D, Plastino M, Colica C, et al. Opioid antagonist naltrexone for the treatment of pathological gambling in Parkinson disease. Clin Neuropharmacol. 2012;35:118-120.
44. Bostwick JM, Hecksel KA, Stevens SR, et al. Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease. Mayo Clin Proc. 2009;84:310-316.
45. Garcia RF, Ordacgi L, Mendlowicz MV, et al. Treatment of juvenile Parkinson disease and the recurrent emergence of pathologic gambling. Cogn Behav Neurol. 2007;20:11-14.
46. Pignatti R, Brioschi A, Mauro A, et al. Selective IGT decision-making impairment in a patient with juvenile Parkinson's disease and pathological gambling: a role for dopaminergic therapy? Neurocase. 2012;18:503-513.
47. Tschopp L, Salazar Z, Gomez Botello MT, et al. Impulse control disorder and piribedil: report of 5 cases. Clin Neuropharmacol. 2010;33:11-13.
48. Wilson L, Sheehan J, Thorpe M. Three cases of impulse control disorder in Parkinson's disease patients receiving dopamine replacement therapy. Ir Med J. 2013;106:24-25.
49. Montastruc JL, Schmitt L, Bagheri H. Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine [in French]. Rev Neurol (Paris). 2003;159:441-443.
50. Kurlan R. Disabling repetitive behaviors in Parkinson's disease. Mov Disord. 2004;19:433-437.
51. Larner AJ. Medical hazards of the internet: gambling in Parkinson's disease. Mov Disord. 2006;21:1789.
52. Wong SH, Cowen Z, Allen EA, et al. Internet gambling and other pathological gambling in Parkinson's disease: a case series. Mov Disord. 2007;22:591-593.
53. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.
54. Olley J, Blaszczynski A, Lewis S. Dopaminergic medication in Parkinson's disease and problem gambling. J Gambl Stud. 2015;31:1085-1106.
55. de Rezende Costa FH, Zuma Rosso AL, Maultasch H, et al. Depression in Parkinson's disease: diagnosis and treatment. Arq Neuropsichiatr. 2012;70:617-620.
56. Stefanova E, Ziropadja L, Petrovic M, et al. Screening for anxiety symptoms in Parkinson disease: a cross-sectional study. J Geriatr Psychiatry Neurol. 2013;26:34-40.
57. Grachev ID. Dopamine transporter imaging with [123I]FP-CIT (DaTSCAN) in Parkinson's diseasewith depressive symptoms: a biological marker for causal relationships? J Neurol Neurosurg Psychiatry. 2014; 85:130-131.
58. Vriend C, Raijmakers P, Veltman DJ, et al. Depressive symptoms in Parkinson's disease are related to reduced [123I]FP-CIT binding in the caudate nucleus. J Neurol Neurosurg Psychiatry. 2014;85:159-164.
59. Mueser KT, Gingerich S. Treatment of co-occurring psychotic and substance use disorders. Soc Work Public Health. 2013;28:424-439.
60. Cloninger CR, Svrakic DM, Przybeck TR. A psychobiological model of temperament and character. Arch Gen Psychiatry. 1993;50:975-990.
61. Vitaro F, Arseneault L, Tremblay RE. Impulsivity predicts problem gambling in low SES adolescent males. Addiction. 1999;94:565-575.
62. Milivojevic D, Milovanovic SD, Jovanovic M, et al. Temperament and character modify risk of drug addiction and influence choice of drugs. Am J Addict. 2012;21:462-467.
63. Zhornitsky S, Rizkallah E, Pampoulova T, et al. Sensation-seeking, social anhedonia, and impulsivity in substance use disorder patients with and without schizophrenia and in non-abusing schizophrenia patients. Psychiatry Res. 2012;200:237-241.
64. McNamara P, Durso R, Harris E. Alterations of the sense of self and personality in Parkinson's disease. Int J Geriatr Psychiatry. 2008;23:79-84.
65. Stoffers D, Berendse HW, Deijen JB, et al. Motor perseveration is an early sign of Parkinson's disease. Neurology. 2001;57:2111-2113.
66. Gonzales N, MoraM, Gutierrez-Maldonado J, et al. Pathological gambling and age: differences in personality, psychopathology and response to treatment variables. Addict Behav. 2005;30:380-388.
67. Bonnaire C, Varescon I, Bungener C. Sensation seeking in a French population of horse betting gamblers: comparison between pathological and regular [in French]. Encéphale. 2007;33:798-804.
68. Cilia R, Cho SS, van Eimeren T, et al. Pathological gambling in patients with Parkinson's disease is associated with fronto-striatal disconnection: a path modeling analysis. Mov Disord. 2011;26:225-233.
69. Nelson SE, Laplante DA, Labrie RA, et al. The proxy effect: gender and gambling problem trajectories of Iowa gambling treatment program participants. J Gambl Stud. 2006;22:221-240.
70. Kessler RC, Hwang I, LaBrie R, et al. DSM-IV pathological gambling in the National Comorbidity Survey Replication. Psychol Med. 2008;38: 1351-1360.
71. Kim SW, Grant JE, Eckert ED, et al. Pathological gambling and mood disorders: clinical associations and treatment implications. J Affect Disord. 2006;92:109-116.
72. Aragay N, Roca A, Garcia B, et al. Pathological gambling in a psychiatric sample. Compr Psychiatry. 2012;53:9-14.
73. Pearce J, Mason K, Hiscock R, et al. A national study of neighbourhood access to gambling opportunities and individual gambling behaviour. J Epidemiol Community Health. 2008;62:862-868.
74. Currie SR, Hodgins DC, Wang J, et al. Risk of harm among gamblers in the general population as a function of level of participation in gambling activities. Addiction. 2006;101:570-580.
75. Emond MS, Marmurek HH. Gambling related cognitions mediate the association between thinking style and problem gambling severity. J Gambl Stud. 2010;26:257-267.
76. Xian H, Shah KR, Phillips SM, et al. Association of cognitive distortions with problem and pathological gambling in adult male twins. Psychiatry Res. 2008;160:300-307.
77. Prentice KJ, Gold JM, Carpenter WT Jr. Optimistic bias in the perception of personal risk: patterns in schizophrenia. Am J Psychiatry. 2005;162:507-512.